Cenyx Biotech, Inc.
June 16, 2025
Company Presentation
Inflammation
Cenyx Biotech Inc. is a pioneering nanomedicine company developing first-in-human cerium oxide-based nanozyme for acute and chronic inflammatory diseases with high unmet needs. Our lead candidate, CX213, has received FDA IND approval and orphan drug designation for SAH-induced inflammation, a life-threatening condition with no approved therapy. Phase 1 trials will begin in 2Q 2025 in the US, with an expedited market entry strategy targeting commercialization by 2028. Our second pipeline, CX301, is advancing toward IND approval by 2Q 2025 for multiple types of acute kidney injury. CENYX leverages its proprietary INNOSURFACE® platform to develop next-gen anti-inflammatory nanozymes across multiple delivery routes. Supported by national grants and in-house GMP manufacturing, we aim to transform inflammatory disease treatment. CENYX seeks strategic partners to accelerate clinical progress and global commercialization.
Company HQ City:
Seoul
Company HQ State:
Seoul
Company HQ Country:
Korea, Republic of
Year Founded:
2016
Lead Product in Development:
CX213 (cerium oxide-based nanozyme)
CEO
Seung-Hoon Lee, MD, PhD, FAHA
Year Founded
2016
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
4
When you expect your next catalyst update?
CX213 first-in-human (Phase 1a) clinical trial
What is your next catalyst (value inflection) update?
CX213 Phase 1a initiation by April 2025, final data available by September 2025
Website
https://www.cenyxbiotech.com/en/
Primary Speaker
)
)
)
)
){kind=logo}
)
){kind=logo}